相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
James M. Rae et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
G. Viale et al.
ANNALS OF ONCOLOGY (2011)
Pharmacogenetics of Endocrine Therapy for Breast Cancer
Michaela J. Higgins et al.
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011 (2011)
Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
L. Madlensky et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study
Marco Colleoni et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
CYP2D6 Inhibition and Breast Cancer Recurrence in a Population-Based Study in Denmark
Timothy L. Lash et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
High-efficiency genotype analysis from formalin-fixed, paraffin-embedded tumor tissues
M. J. Sikora et al.
PHARMACOGENOMICS JOURNAL (2011)
Endoxifen, a New Cornerstone of Breast Cancer Therapy: Demonstration of Safety,Tolerability, and Systemic Bioavailability in Healthy Human Subjects
A. Ahmad et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
Roberta Ferraldeschi et al.
PHARMACEUTICALS (2010)
Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort
N. Lynn Henry et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor α for Degradation in Breast Cancer Cells
Xianglin Wu et al.
CANCER RESEARCH (2009)
Pharmacogenomics of Tamoxifen Therapy
Hiltrud Brauch et al.
CLINICAL CHEMISTRY (2009)
Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
Werner Schroth et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer
Henning Mouridsen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients
J. M. Rae et al.
PHARMACOGENOMICS JOURNAL (2009)
Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer:: A modeling analysis
Rinaa S. Punglia et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial
Jack Cuzick et al.
LANCET ONCOLOGY (2008)
Tamoxifen, hot flashes and recurrence in breast cancer
Joanne E. Mortimer et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system
Clifford A. Hudis et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer:: Update of study BIG 1-98
Alan S. Coates et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes:: Data from the Italian tamoxifen trial
Bernardo Bonanni et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism:: Implication for optimization of breast cancer treatment
Silvana Borges et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes
MP Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial
IE Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen
YC Lim et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
Y Jin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen
MD Johnson et al.
BREAST CANCER RESEARCH AND TREATMENT (2004)
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6
Z Desta et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
V Stearns et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen
M Dowsett et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2003)
Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests
JM Robins et al.
BIOMETRICS (2000)
分享论文
